Cargando…
Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer
Bavituximab is a an unconjugated, chimeric immunoglobulin G1 (IgG1) monoclonal antibody directed against the phosphatidylserine (PS) expressed on tumor endothelium, with a specific mechanism of action. PS is an anionic membrane phospholipid, physiologically restricted to the internal membrane leafle...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217514/ https://www.ncbi.nlm.nih.gov/pubmed/28210141 http://dx.doi.org/10.2147/LCTT.S37981 |
_version_ | 1782492121505202176 |
---|---|
author | Stasi, Irene Cappuzzo, Federico |
author_facet | Stasi, Irene Cappuzzo, Federico |
author_sort | Stasi, Irene |
collection | PubMed |
description | Bavituximab is a an unconjugated, chimeric immunoglobulin G1 (IgG1) monoclonal antibody directed against the phosphatidylserine (PS) expressed on tumor endothelium, with a specific mechanism of action. PS is an anionic membrane phospholipid, physiologically restricted to the internal membrane leaflet; various pathophysiologic processes cause the exposure of PS on the external membrane leaflet. Bavituximab, once bound, starts up host effector activities, such as antibody dependent cellular cytotoxicity, causing vessel destruction and enhancing antitumor immunity. Phase I clinical trials of bavituximab administered as monotherapy or in combination with other chemotherapeutic agents in adults with pretreated solid tumors have been accomplished, indicating that bavituximab can be safely dispensed weekly, with a recommended dose of 1 and 3 mg/kg. A Phase II randomized, placebo-controlled trial of bavituximab plus docetaxel, in the second-line therapy setting of locally advanced or metastatic non-small-cell lung cancer, has been conducted and recently presented, suggesting a clinical benefit of the combination, with an overall response rate of 17% and median overall survival of more than 11 months. A Phase III trial is currently ongoing. Bavituximab has been studied in combination with platinum-based doublets with promising results. In the present paper we summarize the preclinical development and clinical experience with bavituximab in non-small-cell lung cancer. |
format | Online Article Text |
id | pubmed-5217514 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-52175142017-02-16 Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer Stasi, Irene Cappuzzo, Federico Lung Cancer (Auckl) Review Bavituximab is a an unconjugated, chimeric immunoglobulin G1 (IgG1) monoclonal antibody directed against the phosphatidylserine (PS) expressed on tumor endothelium, with a specific mechanism of action. PS is an anionic membrane phospholipid, physiologically restricted to the internal membrane leaflet; various pathophysiologic processes cause the exposure of PS on the external membrane leaflet. Bavituximab, once bound, starts up host effector activities, such as antibody dependent cellular cytotoxicity, causing vessel destruction and enhancing antitumor immunity. Phase I clinical trials of bavituximab administered as monotherapy or in combination with other chemotherapeutic agents in adults with pretreated solid tumors have been accomplished, indicating that bavituximab can be safely dispensed weekly, with a recommended dose of 1 and 3 mg/kg. A Phase II randomized, placebo-controlled trial of bavituximab plus docetaxel, in the second-line therapy setting of locally advanced or metastatic non-small-cell lung cancer, has been conducted and recently presented, suggesting a clinical benefit of the combination, with an overall response rate of 17% and median overall survival of more than 11 months. A Phase III trial is currently ongoing. Bavituximab has been studied in combination with platinum-based doublets with promising results. In the present paper we summarize the preclinical development and clinical experience with bavituximab in non-small-cell lung cancer. Dove Medical Press 2014-08-28 /pmc/articles/PMC5217514/ /pubmed/28210141 http://dx.doi.org/10.2147/LCTT.S37981 Text en © 2014 Stasi and Cappuzzo. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Stasi, Irene Cappuzzo, Federico Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer |
title | Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer |
title_full | Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer |
title_fullStr | Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer |
title_full_unstemmed | Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer |
title_short | Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer |
title_sort | profile of bavituximab and its potential in the treatment of non-small-cell lung cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217514/ https://www.ncbi.nlm.nih.gov/pubmed/28210141 http://dx.doi.org/10.2147/LCTT.S37981 |
work_keys_str_mv | AT stasiirene profileofbavituximabanditspotentialinthetreatmentofnonsmallcelllungcancer AT cappuzzofederico profileofbavituximabanditspotentialinthetreatmentofnonsmallcelllungcancer |